Spotlight: Longevity in Context
As societies age, we talk a lot about Alzheimer's, stroke, and dementia, but too rarely do we mention another silent force accelerating brain decline: major depressive disorder (MDD).
At first glance, depression and aging seem like separate challenges. But growing evidence shows they’re deeply interwoven, sharing biological mechanisms and amplifying each other’s effects.
Studies reveal that MDD is linked to accelerated biological brain aging. Brain scans show reduced gray matter, altered white matter, and disrupted connectivity in key areas like the hippocampus and prefrontal cortex. The "Brain Age Gap", a biomarker comparing biological to chronological age, is significantly higher in people with MDD, suggesting their brains age faster than expected (PMID: 34881077).
And it’s not just structural. Telomere shortening, oxidative stress, and chronic inflammation (all hallmarks of aging) are also elevated in individuals with mood disorders, including bipolar disorder (PMIDs: 34881077; 35392273). Epigenetic clocks tick faster in those with MDD, especially after early-life adversity, which reshapes gene expression, mitochondrial function, and immune regulation for life (PMID: 35392273).
This matters because older adults are one of the fastest-growing demographics, and depression in later life is often missed, under-treated, or dismissed as “normal.” But it’s not. It’s a warning sign of broader neurobiological decline. Even renowned neuroscientist Dr. Andrew Huberman has dedicated a full series to highlighting how chronic depression alters brain circuitry and the importance of addressing it through science-backed interventions.
And, we can’t ignore the economic toll. MDD already costs over $300 billion annually in the U.S. alone. Add the rising costs of cognitive decline, and the burden becomes unsustainable. Yet we still lack predictive tools that integrate depression, aging biomarkers, and genetic risk. And current treatments often fail to address the root drivers, particularly the epigenetic and mitochondrial dysfunction underlying both affective disorders and aging.
Professor Richard Siow, Director of Ageing Research at King's College London, puts it clearly: “We need a more integrated approach to brain aging, one that connects vascular health, mood disorders, and neurodegeneration. It’s time for bold, cross-disciplinary strategies that prioritize prevention.”
If you want to support translational brain health research, we’d love to hear from you. MDD is just one of many psychiatric disorders that affect longevity. It’s time to direct adequate resources to this area and bring mental health into the longevity conversation.
As societies age, we talk a lot about Alzheimer's, stroke, and dementia, but too rarely do we mention another silent force accelerating brain decline: major depressive disorder (MDD).
At first glance, depression and aging seem like separate challenges. But growing evidence shows they’re deeply interwoven, sharing biological mechanisms and amplifying each other’s effects.
Studies reveal that MDD is linked to accelerated biological brain aging. Brain scans show reduced gray matter, altered white matter, and disrupted connectivity in key areas like the hippocampus and prefrontal cortex. The "Brain Age Gap", a biomarker comparing biological to chronological age, is significantly higher in people with MDD, suggesting their brains age faster than expected (PMID: 34881077).
And it’s not just structural. Telomere shortening, oxidative stress, and chronic inflammation (all hallmarks of aging) are also elevated in individuals with mood disorders, including bipolar disorder (PMIDs: 34881077; 35392273). Epigenetic clocks tick faster in those with MDD, especially after early-life adversity, which reshapes gene expression, mitochondrial function, and immune regulation for life (PMID: 35392273).
This matters because older adults are one of the fastest-growing demographics, and depression in later life is often missed, under-treated, or dismissed as “normal.” But it’s not. It’s a warning sign of broader neurobiological decline. Even renowned neuroscientist Dr. Andrew Huberman has dedicated a full series to highlighting how chronic depression alters brain circuitry and the importance of addressing it through science-backed interventions.
And, we can’t ignore the economic toll. MDD already costs over $300 billion annually in the U.S. alone. Add the rising costs of cognitive decline, and the burden becomes unsustainable. Yet we still lack predictive tools that integrate depression, aging biomarkers, and genetic risk. And current treatments often fail to address the root drivers, particularly the epigenetic and mitochondrial dysfunction underlying both affective disorders and aging.
Professor Richard Siow, Director of Ageing Research at King's College London, puts it clearly: “We need a more integrated approach to brain aging, one that connects vascular health, mood disorders, and neurodegeneration. It’s time for bold, cross-disciplinary strategies that prioritize prevention.”
If you want to support translational brain health research, we’d love to hear from you. MDD is just one of many psychiatric disorders that affect longevity. It’s time to direct adequate resources to this area and bring mental health into the longevity conversation.